CD8A and melanoma: The mutational and neoantigen load (125) and a high ratio of CD8+ density in the intratumoral region have also been related to clinical benefit to Ipilimumab in melanoma (126), while PD-L1 staining by IHC alone does not seem to be predictive (127).